Financial Statements 143 10 Other investments 2009 2008 2007 $m $m $m Non-current investments Equity securities available for sale 184 156 182 184 156 182 Current investments Equity securities held for trading 18 51 31 Fixed deposits 1,466 54 60 1,484 105 91 Impairment charges of $18m in respect of available for sale securities are included in other operating income and expense in profit 2008: $25m: 2007: $18m.
11 Inventories 2009 2008 2007 $m $m $m Raw materials and consumables 445 409 579 Inventories in process 726 631 806 Finished goods and goods for re-sale 579 596 734 1,750 1,636 2,119 Inventory write-offs in the year amounted to $83m 2008: $51m: 2007: $95m.
12 Trade and other receivables 2009 2008 2007 $m $m $m Amounts due within one year Trade receivables 5,863 5,657 5,415 Less: Amounts provided for doubtful debts Note 16 81 99 89 5,782 5,558 5,326 Other receivables 1,170 978 593 Prepayments and accrued income 580 552 510 7,532 7,088 6,429 Amounts due after more than one year Other receivables 27 44 54 Prepayments and accrued income 150 129 185 177 173 239 7,709 7,261 6,668 Provision for doubtful debts Balance at beginning of year 99 89 52 Income statement credit charge 20 23 34 Amounts utilised, exchange and other movements 2 13 3 Balance at end of year 81 99 89 13 Cash and cash equivalents 2009 2008 2007 $m $m $m Cash at bank and in hand 1,077 1,039 1,403 Short term deposits 8,841 3,247 4,464 Cash and cash equivalents 9,918 4,286 5,867 Unsecured bank overdrafts 90 163 140 Cash and cash equivalents in the cash flow statement 9,828 4,123 5,727 The Groups insurance subsidiaries hold cash and short term investments totalling $173m 2008: $400m: 2007: $347m, of which $49m 2008: $278m: 2007: $257m is required to meet insurance solvency requirements and which, as a result, is not readily available for the general purposes of the Group.
AstraZeneca Annual Report and Form 20-F Information 2009 AstraZeneca Annual Report and Form 20-F Information 2009
